BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12798640)

  • 1. CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.
    Harcourt JL; Brown MP; Anderson LJ; Tripp RA
    Vaccine; 2003 Jun; 21(21-22):2964-79. PubMed ID: 12798640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles.
    Harcourt JL; Anderson LJ; Sullender W; Tripp RA
    Vaccine; 2004 Jun; 22(17-18):2248-60. PubMed ID: 15149784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome.
    Xu J; Ding Y; Yang Y
    Viral Immunol; 2008 Dec; 21(4):483-9. PubMed ID: 19115938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.
    Hwang HS; Kwon YM; Lee JS; Yoo SE; Lee YN; Ko EJ; Kim MC; Cho MK; Lee YT; Jung YJ; Lee JY; Li JD; Kang SM
    Antiviral Res; 2014 Oct; 110():115-23. PubMed ID: 25110201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response.
    Ma Y; Jiao YY; Yu YZ; Jiang N; Hua Y; Zhang XJ; Fu YH; Peng XL; Zheng YP; Anderson LJ; He JS
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29342954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse.
    Tripp RA; Jones L; Anderson LJ; Brown MP
    J Immunol; 2000 Jun; 164(11):5913-21. PubMed ID: 10820273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
    Lindell DM; Morris SB; White MP; Kallal LE; Lundy PK; Hamouda T; Baker JR; Lukacs NW
    PLoS One; 2011; 6(7):e21823. PubMed ID: 21789184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.
    Zeng R; Zhang H; Hai Y; Cui Y; Wei L; Li N; Liu J; Li C; Liu Y
    J Virol; 2012 Apr; 86(8):4505-17. PubMed ID: 22301139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
    Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
    Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
    Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
    Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.